YH14618 + YH14618 + YH14618 + Placebo
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Degenerative Disc Disease
Conditions
Degenerative Disc Disease
Trial Timeline
May 1, 2012 → Jul 1, 2014
NCT ID
NCT01526330About YH14618 + YH14618 + YH14618 + Placebo
YH14618 + YH14618 + YH14618 + Placebo is a phase 1/2 stage product being developed by Yuhan for Degenerative Disc Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01526330. Target conditions include Degenerative Disc Disease.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01526330 | Phase 1/2 | Completed |
Competing Products
17 competing products in Degenerative Disc Disease
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85